2C08

2C08, also known as 2,5-dimethoxy-8-hydroxyamphetamine, is a synthetic psychedelic compound belonging to the phenethylamine class. It is a derivative of the natural compound mescaline, with structural similarities to other 2C-series compounds such as 2C-B (2,5-dimethoxy-4-bromophenethylamine) and 2C-T-2 (2,5-dimethoxy-4-ethylthiophenethylamine). The compound was first synthesized in the 1970s by Alexander Shulgin, a chemist known for his extensive research on psychedelic substances. Shulgin documented its effects in his book *PiHKAL: A Chemical Love Story*, describing it as a potent hallucinogen with a relatively short duration of action.

2C08 is typically consumed orally, often in doses ranging from 10 to 30 milligrams, though individual responses can vary significantly. Users commonly report experiences characterized by visual distortions, enhanced sensory perception, introspection, and a sense of euphoria. The compound is known for producing vivid, often geometric hallucinations, as well as a mild stimulant effect. Its effects generally peak within 60 to 90 minutes and subside within 4 to 6 hours.

Due to its psychoactive properties, 2C08 is classified as a controlled substance in many countries, including the United States under the Federal Analog Act, which prohibits substances with a chemical structure similar to those of controlled drugs. Its legal status varies globally, with some jurisdictions explicitly banning it, while others regulate it under broader drug laws. The compound is not approved for medical or recreational use and is primarily encountered in underground chemical research and illicit markets.

Research on 2C08 remains limited, and its long-term effects on human health are not well understood. Like other psychedelics, it carries risks such as adverse psychological reactions, particularly in individuals with preexisting mental health conditions. Responsible use, proper setting, and dosage awareness are emphasized by advocates of psychedelic research to mitigate potential harm.